Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2022-09-24 , DOI: 10.1002/alz.12787
Alexa Pichet Binette ₁ , Shorena Janelidze ₁ , Nicholas Cullen ₁ , Jeffrey L Dage ₂ , Randall J Bateman ₃ , Henrik Zetterberg _{4,

5,

6,

7,

8} , Kaj Blennow _{4,

5} , Erik Stomrud _{1,

9} , Niklas Mattsson-Carlgren _{1,

10,

11} , Oskar Hansson _{1,

9}

Affiliation

Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Neurology, Washington University School of Medicine, St Louis, Missouri, USA.
Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL, London, UK.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
Memory Clinic, Skåne University Hospital, Malmö, Sweden.
Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden.
Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.

Plasma biomarkers will likely revolutionize the diagnostic work-up of Alzheimer's disease (AD) globally. Before widespread use, we need to determine if confounding factors affect the levels of these biomarkers, and their clinical utility.

中文翻译：